Mark Ragosa
Director of Finance/CFO at KINIKSA PHARMACEUTICALS, LTD.
Net worth: 366 000 $ as of 2024-05-30
Profile
Mark Ragosa is currently the Chief Financial Officer & Director at Kiniksa Pharmaceuticals Corp.
He also holds the position of Chief Financial Officer & Senior Vice President at Kiniksa Pharmaceuticals Ltd.
Mr. Ragosa previously worked as the Director-Investor Relations at Ironwood Pharmaceuticals, Inc. and as a Vice President in the Equities Division at Goldman Sachs & Co. LLC.
He completed his undergraduate degree at Bowdoin College.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-04-25 | 19,253 ( 0.05% ) | 366 000 $ | 2024-05-30 |
Mark Ragosa active positions
Companies | Position | Start |
---|---|---|
KINIKSA PHARMACEUTICALS, LTD. | Director of Finance/CFO | 2020-12-16 |
Kiniksa Pharmaceuticals Corp.
Kiniksa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Part of Kiniksa Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops and commercializes therapeutic medicines for patients suffering from debilitating diseases. The company is based in Lexington, MA. The CEO of the company is Sanj K. Patel. | Director of Finance/CFO | - |
Former positions of Mark Ragosa
Companies | Position | End |
---|---|---|
IRONWOOD PHARMACEUTICALS, INC. | Investor Relations Contact | 2018-04-30 |
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Corporate Officer/Principal | - |
Training of Mark Ragosa
Bowdoin College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
Private companies | 2 |
---|---|
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Finance |
Kiniksa Pharmaceuticals Corp.
Kiniksa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Part of Kiniksa Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops and commercializes therapeutic medicines for patients suffering from debilitating diseases. The company is based in Lexington, MA. The CEO of the company is Sanj K. Patel. | Health Technology |
- Stock Market
- Insiders
- Mark Ragosa